NO20034031L - Substituerte pyrazol- og tiazolpyrimidiner - Google Patents
Substituerte pyrazol- og tiazolpyrimidinerInfo
- Publication number
- NO20034031L NO20034031L NO20034031A NO20034031A NO20034031L NO 20034031 L NO20034031 L NO 20034031L NO 20034031 A NO20034031 A NO 20034031A NO 20034031 A NO20034031 A NO 20034031A NO 20034031 L NO20034031 L NO 20034031L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- diseases
- disease
- treatment
- tinnitus
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- UVRHPZOOCXESOY-UHFFFAOYSA-N pyrimidine;1,3-thiazole Chemical class C1=CSC=N1.C1=CN=CN=C1 UVRHPZOOCXESOY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000025157 Oral disease Diseases 0.000 abstract 2
- 208000009205 Tinnitus Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000030194 mouth disease Diseases 0.000 abstract 2
- 231100000886 tinnitus Toxicity 0.000 abstract 2
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 abstract 1
- 206010065040 AIDS dementia complex Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 241000976983 Anoxia Species 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010048962 Brain oedema Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010028921 Neonatal anoxia Diseases 0.000 abstract 1
- 206010028923 Neonatal asphyxia Diseases 0.000 abstract 1
- 206010050081 Neonatal hypoxia Diseases 0.000 abstract 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000007953 anoxia Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 208000006752 brain edema Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 201000002491 encephalomyelitis Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 208000033300 perinatal asphyxia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 150000008634 thiazolopyrimidines Chemical class 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001112197 DE10112197A1 (de) | 2001-03-14 | 2001-03-14 | Substituierte Pyrazolo- und Thiazolopyrimidine |
| DE2001153344 DE10153344A1 (de) | 2001-10-29 | 2001-10-29 | Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren |
| PCT/EP2002/002722 WO2002072585A2 (de) | 2001-03-14 | 2002-03-13 | Substituierte pyrazolo- und thiazolopyrimidine als analgetika |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20034031D0 NO20034031D0 (no) | 2003-09-11 |
| NO20034031L true NO20034031L (no) | 2003-10-21 |
Family
ID=26008763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034031A NO20034031L (no) | 2001-03-14 | 2003-09-11 | Substituerte pyrazol- og tiazolpyrimidiner |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7135568B2 (enExample) |
| EP (2) | EP1637533B1 (enExample) |
| JP (1) | JP2004527508A (enExample) |
| KR (1) | KR20030082982A (enExample) |
| CN (1) | CN1318422C (enExample) |
| AT (2) | ATE404568T1 (enExample) |
| AU (1) | AU2002302419B2 (enExample) |
| BR (1) | BR0208244A (enExample) |
| CA (1) | CA2440760C (enExample) |
| CY (1) | CY1105507T1 (enExample) |
| CZ (1) | CZ20032474A3 (enExample) |
| DE (2) | DE50207103D1 (enExample) |
| DK (1) | DK1368355T3 (enExample) |
| ES (2) | ES2311920T3 (enExample) |
| HU (1) | HUP0401211A3 (enExample) |
| IL (2) | IL157895A0 (enExample) |
| MX (1) | MXPA03008291A (enExample) |
| NO (1) | NO20034031L (enExample) |
| NZ (2) | NZ540574A (enExample) |
| PL (1) | PL364388A1 (enExample) |
| PT (1) | PT1368355E (enExample) |
| RU (1) | RU2003129060A (enExample) |
| SK (1) | SK11542003A3 (enExample) |
| WO (1) | WO2002072585A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9447100B2 (en) | 2002-08-26 | 2016-09-20 | Takeda Pharmaceutical Company, Ltd. | Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004076450A1 (en) * | 2003-02-27 | 2004-09-10 | J. Uriach Y Compañia S.A. | Pyrazolopyridine derivates |
| GB0404434D0 (en) | 2004-02-27 | 2004-03-31 | Novartis Ag | Organic compounds |
| WO2005112936A1 (en) * | 2004-05-14 | 2005-12-01 | The Regents Of The University Of Michigan | Compositions and methods relating to protein kinase inhibitors |
| TW200618800A (en) * | 2004-08-03 | 2006-06-16 | Uriach Y Compania S A J | Heterocyclic compounds |
| EP1736475A1 (en) * | 2005-06-21 | 2006-12-27 | Ferrer Internacional, S.A. | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates |
| KR100838692B1 (ko) | 2007-07-11 | 2008-06-16 | 한국화학연구원 | 7-(3′,4′-디알콕시페닐)-4,5,6,7-테트라히드로피라졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는천식 및 만성폐쇄성 폐질환을 포함한 염증관련 질환,관절염, 아토피 피부염, 암 및 뇌질환의 치료 및 예방을위한 약제학적 조성물 |
| KR20100119776A (ko) * | 2008-01-24 | 2010-11-10 | 알라 캠, 엘엘씨 | 2-알킬아미노-3-아릴설포닐-사이클로알카노[ｅ 또는 ｄ]피라졸로[1,5-Ａ]피리미딘/세로토닌 5-ＨＴ6 수용체의 길항제, 이의 제조방법 및 이의 용도 |
| RU2374249C1 (ru) * | 2008-09-17 | 2009-11-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[е ИЛИ d]ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| US8629154B2 (en) * | 2008-01-24 | 2014-01-14 | Andrey Alexandrovich Ivashchenko | Substituted cycloalcano[e and d] pyrazolo [1,5-a]pyrimidines/antagonists of serotonin 5-HT6 receptors and methods for production and the use thereof |
| RU2369600C1 (ru) * | 2008-01-24 | 2009-10-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| RU2376291C1 (ru) * | 2008-05-07 | 2009-12-20 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 3,5-ДИАМИНО-4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 2-АМИНО-3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| CA2755968C (en) * | 2008-10-06 | 2019-03-19 | Andrey Alexandrovich Ivashchenko | Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof |
| TW201035103A (en) * | 2008-12-22 | 2010-10-01 | Schering Corp | Gamma secretase modulators |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| CN102775412B (zh) * | 2012-08-21 | 2013-05-01 | 四川大学 | 一种镇静催眠的化合物及其制备方法和用途 |
| CN102977106B (zh) * | 2012-12-12 | 2014-12-10 | 中国药科大学 | 一类具有外周镇痛作用的κ阿片受体激动剂 |
| MX363680B (es) | 2013-03-15 | 2019-03-29 | Chromocell Corp | Compuestos moduladores del canal de sodio (nav1. 7) y sus usos para el tratamiento del dolor neuropatico, nociceptivo o inflamatorio. |
| CN105611923B (zh) * | 2013-09-10 | 2019-08-23 | 卓莫赛尔公司 | 用于治疗疼痛和糖尿病的钠通道调节剂 |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CN108473497B (zh) | 2015-10-16 | 2021-09-10 | 卫材R&D 管理有限公司 | Ep4拮抗剂 |
| WO2018133835A1 (en) * | 2017-01-20 | 2018-07-26 | National Institute Of Biological Sciences, Beijing | Nucleoside analogue regulating mammalian circadian rhythm |
| BR112019022465A2 (pt) * | 2017-04-27 | 2020-05-12 | Takeda Pharmaceutical Company Limited | Composto, medicamento, métodos para antagonizar um receptor sensor de cálcio em um mamífero e para prevenir ou tratar insuficiência cardíaca e hipertensão pulmona em um mamífero, e, uso do composto. |
| CN110582499B (zh) | 2017-04-27 | 2022-04-29 | 武田药品工业株式会社 | 杂环化合物 |
| CN113354644B (zh) * | 2020-03-04 | 2023-07-04 | 烟台药物研究所 | 一类用作dpp-iv抑制剂的吡唑并嘧啶结构的化合物及应用 |
| CN116023382B (zh) * | 2023-02-22 | 2025-09-23 | 北京师范大学 | 一种合成手性四氢吡唑并[1,5-a]嘧啶的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4847256A (en) * | 1986-10-16 | 1989-07-11 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines |
| EP0264773A1 (en) | 1986-10-16 | 1988-04-27 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines |
| NZ233641A (en) * | 1989-05-16 | 1992-07-28 | Merrell Dow Pharma | Quinoline and thienopyridine derivatives and excitatory amino acid antagonistic pharmaceutical compositions |
| GB9206266D0 (en) * | 1992-03-23 | 1992-05-06 | Merck Sharp & Dohme | Therapeutic agents |
| FR2717812B1 (fr) * | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant. |
| FR2722786B1 (fr) * | 1994-07-20 | 1996-08-23 | Rhone Poulenc Rorer Sa | Derives de 4-hydroxy-3-phenyl-indeno(1,2-b)pyridine-2(1h)- one, leur preparation et les medicaments les contenant |
| DE4444815A1 (de) * | 1994-12-15 | 1996-06-20 | Merck Patent Gmbh | Thienopyridone |
| JP2003288537A (ja) | 2000-09-25 | 2003-10-10 | Everyd.Com:Kk | 商品宅配システムおよび方法 |
| DE10112197A1 (de) | 2001-03-14 | 2002-09-19 | Gruenenthal Gmbh | Substituierte Pyrazolo- und Thiazolopyrimidine |
-
2002
- 2002-03-13 AT AT05026811T patent/ATE404568T1/de not_active IP Right Cessation
- 2002-03-13 MX MXPA03008291A patent/MXPA03008291A/es active IP Right Grant
- 2002-03-13 JP JP2002571501A patent/JP2004527508A/ja active Pending
- 2002-03-13 RU RU2003129060/04A patent/RU2003129060A/ru not_active Application Discontinuation
- 2002-03-13 CZ CZ20032474A patent/CZ20032474A3/cs unknown
- 2002-03-13 DK DK02729998T patent/DK1368355T3/da active
- 2002-03-13 DE DE50207103T patent/DE50207103D1/de not_active Expired - Lifetime
- 2002-03-13 WO PCT/EP2002/002722 patent/WO2002072585A2/de not_active Ceased
- 2002-03-13 PL PL02364388A patent/PL364388A1/xx not_active Application Discontinuation
- 2002-03-13 SK SK1154-2003A patent/SK11542003A3/sk unknown
- 2002-03-13 BR BR0208244-6A patent/BR0208244A/pt not_active Application Discontinuation
- 2002-03-13 NZ NZ540574A patent/NZ540574A/en unknown
- 2002-03-13 CN CNB028096886A patent/CN1318422C/zh not_active Expired - Fee Related
- 2002-03-13 ES ES05026811T patent/ES2311920T3/es not_active Expired - Lifetime
- 2002-03-13 ES ES02729998T patent/ES2263779T3/es not_active Expired - Lifetime
- 2002-03-13 DE DE50212652T patent/DE50212652D1/de not_active Expired - Lifetime
- 2002-03-13 PT PT02729998T patent/PT1368355E/pt unknown
- 2002-03-13 EP EP05026811A patent/EP1637533B1/de not_active Expired - Lifetime
- 2002-03-13 AT AT02729998T patent/ATE328886T1/de not_active IP Right Cessation
- 2002-03-13 CA CA2440760A patent/CA2440760C/en not_active Expired - Fee Related
- 2002-03-13 AU AU2002302419A patent/AU2002302419B2/en not_active Ceased
- 2002-03-13 EP EP02729998A patent/EP1368355B1/de not_active Expired - Lifetime
- 2002-03-13 HU HU0401211A patent/HUP0401211A3/hu unknown
- 2002-03-13 KR KR10-2003-7011953A patent/KR20030082982A/ko not_active Withdrawn
- 2002-03-13 NZ NZ528639A patent/NZ528639A/en unknown
- 2002-03-13 IL IL15789502A patent/IL157895A0/xx unknown
-
2003
- 2003-09-11 NO NO20034031A patent/NO20034031L/no not_active Application Discontinuation
- 2003-09-11 IL IL157895A patent/IL157895A/en not_active IP Right Cessation
- 2003-09-12 US US10/660,794 patent/US7135568B2/en not_active Expired - Fee Related
-
2006
- 2006-07-05 CY CY20061100930T patent/CY1105507T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9447100B2 (en) | 2002-08-26 | 2016-09-20 | Takeda Pharmaceutical Company, Ltd. | Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20034031L (no) | Substituerte pyrazol- og tiazolpyrimidiner | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| WO2003053330A3 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3 | |
| UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| NO174772C (no) | Analogifremgangsmåte ved fremstilling av terapeutisk aktive piperazinylderivater | |
| PT1427708E (pt) | Derivados amino-ftalazinona activos como inibidors de cinase, processo para a sua preparação e composições farmacêuticas contendo-os | |
| MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
| ATE253918T1 (de) | Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel | |
| JPS5976086A (ja) | プテリジン化合物 | |
| US11897876B2 (en) | Isoxazolidines as RIPK1 inhibitors and use thereof | |
| CA2534532A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
| SG151336A1 (en) | 1,3,4-oxadiazol-2-ones as ppar delta | |
| MY142431A (en) | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | |
| WO2005097762A3 (en) | 1,3,4-oxadiazol-2-ones as ppar delta modulators | |
| KR20160115931A (ko) | Ｐｄｅ１ 억제제로서의 헥사히드로푸로피롤 | |
| CA2534529A1 (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
| WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
| CN114315689B (zh) | 二硫烷基邻苯二甲酰亚胺类化合物、其制备方法和用途 | |
| EP4573090A1 (en) | Isoxazolidines as ripk1 inhibitors and use thereof | |
| CN117143027B (zh) | 3-苄氧基-6-羟苯基哒嗪类化合物及其制备方法和用途 | |
| GEP20063960B (en) | New fluorinated benzothiadiazine, a process for their preparation and pharmaceutical compositions contained them | |
| WO2014068171A1 (en) | N-substituted 4-aminophenols and corresponding quinone imines | |
| WO2003004460A3 (en) | Succinic acid derivatives | |
| WO2005095361A8 (en) | Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |